Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024. In the quarter to June 2026, revenue grew 5.57%, EPS fell 125.0%, free cash flow grew 42.5% and total debt fell 68.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow CTKB
Cytek Biosciences, Inc. (CTKB) Beneish M-score
Cytek Biosciences, Inc.'s Beneish M-score for fiscal 2025 is −3.30; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −3.30 | (0.55) |
| FY2024 | −2.75 | (0.46) |
| FY2023 | −2.29 | (0.57) |
| FY2022 | −1.71 | 0.02 |
| FY2021 | −1.73 | 0.19 |
| FY2020 | −1.92 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 1.03 | — | 0.94 | |
| Gross margin index | 1.07 | — | 0.56 | |
| Asset quality index | 0.66 | — | 0.26 | |
| Sales growth index | 1.01 | — | 0.90 | |
| Depreciation index | 0.92 | — | 0.11 | |
| SG&A index | 1.17 | — | −0.20 | |
| Total accruals to total assets | (0.13) | — | −0.63 | |
| Leverage index | 1.23 | — | −0.40 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −3.30 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| PACB Pacific Biosciences of California, Inc. compare | −5.1× |
| CTKB Cytek Biosciences, Inc. | −3.3× |
| AHCO AdaptHealth Corp. compare | −3.3× |
| VREX VAREX IMAGING compare | −3.1× |
| SIBN SiBone compare | −3.1× |
| TCMD Tactile Systems Technology, Inc. compare | −2.8× |
| KIDS OrthoPediatrics Corp. compare | −2.7× |
| INMD InMode Ltd. compare | −2.3× |
| BBNX Beta Bionics, Inc. compare | −1.9× |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI